Cited by 213Radiopharmaceutical Chemistry and ApplicationsMedical Imaging Techniques and ApplicationsProstate Cancer Diagnosis and Treatment

The DOI matches its Crossref record; 31 of the 33 references it cites were found in a registry or an index.

Radiation Dosimetry for 177 Lu-PSMA I&T in Metastatic Castration-Resistant Prostate Cancer: Absorbed Dose in Normal Organs and Tumor Lesions

Open access

Okamoto, Shozo, Thieme, Anne, Allmann, Jakob, D’Alessandria, Calogero, Maurer, Tobias, Retz, Margitta, Tauber, Robert, Heck, Matthias M., Wester, Hans-Juergen, Tamaki, Nagara, Fendler, Wolfgang P., Herrmann, Ken, Pfob, Christian H., Scheidhauer, Klemens, Schwaiger, Markus, Ziegler, Sibylle, Eiber, Matthias·2017·Journal of Nuclear Medicine

DOI 10.2967/jnumed.116.178483

Open this paper in CoChat — free account Open PDF

Abstract

Prostate-specific membrane antigen (PSMA)–targeted radioligand therapy is increasingly used in metastatic castration-resistant prostate cancer. We aimed to estimate the absorbed doses for normal organs and tumor lesions using 177Lu-PSMA I&T (I&T is imaging and therapy) in patients undergoing up to 4 cycles of radioligand therapy. Results were compared with pretherapeutic Glu-NH-CO-NH-Lys-(Ahx)-[68Ga(HBEDCC)] (68Ga-PSMA-HBED-CC) PET. Methods: A total of 34 cycles in 18 patients were analyzed retrospectively. In 15 patients the first, in 9 the second, in 5 the third, and in 5 the fourth cycle was analyzed, respectively. Whole-body scintigraphy was performed at least between 30–120 min, 24 h, and 6–8 d after administration. Regions of interest covering the whole body, organs, and up to 4 tumor lesions were drawn. Organ and tumor masses were derived from pretherapeutic 68Ga-PSMA-HBED-CC PET/CT. Absorbed doses for individual cycles were calculated using OLINDA/EXM. SUVs from pretherapeutic PET were compared with absorbed doses and with change of SUV. Results: The mean whole-body effective dose for all cycles was 0.06 ± 0.03 Sv/GBq. The mean absorbed organ doses were 0.72 ± 0.21 Gy/GBq for the kidneys; 0.12 ± 0.06 Gy/GBq for the liver; and 0.55 ± 0.14 Gy/GBq for the parotid, 0.64 ± 0.40 Gy/GBq for the submandibular, and 3.8 ± 1.4 Gy/GBq for the lacrimal glands. Absorbed organ doses were relatively constant among the 4 different cycles. Tumor lesions received a mean absorbed dose per cycle of 3.2 ± 2.6 Gy/GBq (range, 0.22–12 Gy/GBq). Doses to tumor lesions gradually decreased, with 3.5 ± 2.9 Gy/GBq for the first, 3.3 ± 2.5 Gy/GBq for the second, 2.7 ± 2.3 Gy/GBq for the third, and 2.4 ± 2.2 Gy/GBq for the fourth cycle. SUVs of pretherapeutic PET moderately correlated with absorbed dose (r = 0.44, P < 0.001 for SUVmax; r = 0.43, P < 0.001 for SUVmean) and moderately correlated with the change of SUV (r = 0.478, P < 0.001 for SUVmax, and r = 0.50, P < 0.001 for SUVmean). Conclusion: Organ- and tumor-absorbed doses for 177Lu-PSMA I&T are comparable to recent reports and complement these with information on an excellent correlation between the 4 therapy cycles. With the kidneys representing the critical organ, a cumulative activity of 40 GBq of 177Lu-PSMA I&T appears to be safe and justifiable. The correlation between pretherapeutic SUV and absorbed tumor dose emphasizes the need for PSMA-ligand PET imaging for patient selection.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.2967/jnumed.116.178483

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Tolerance of normal tissue to therapeutic irradiation
Emami, B., Lyman, J., Brown, A., Cola, L., Goitein, M., Munzenrider, J. E., Shank, B., Solin, L. J., & Wesson, M. (1991) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(91)90171-y · Cited by 4,488
International Variation in Prostate Cancer Incidence and Mortality Rates
Center, M. M., Jemal, A., Lortet-Tieulent, J., Ward, E., Ferlay, J., Brawley, O., & Bray, F. (2012) · European Urology · doi:10.1016/j.eururo.2012.02.054 · Cited by 1,521
Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy
Eiber, M. J., Maurer, T., Souvatzoglou, M., Beer, A. J., Ruffani, A., Haller, B., Graner, F.-P., Kübler, H. R., Haberhorn, U., Eisenhut, M., et al. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.154153 · Cited by 995
Self-citation
PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions
Afshar‐Oromieh, A., Malcher, A., Eder, M., Eisenhut, M., Linhart, H., Hadaschik, B. A., Holland‐Letz, T., Giesel, F. L., Kratochwil, C., Haufe, S., et al. (2012) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2298-2 · Cited by 919
Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate in Patients With Endocrine Gastroenteropancreatic Tumors
Kwekkeboom, D. J., Teunissen, J. J., Bakker, W. H., Kooij, P. P., de Herder, W. W., Feelders, R. A., van Eijck, C. H., Esser, J.-P., Kam, B. L., & Krenning, E. P. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.066 · Cited by 657
PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617
Kratochwil, C., Giesel, F. L., Stefanova, M., Benešová, M., Bronzel, M., Afshar-Oromieh, A., Mier, W., Eder, M., Kopka, K., & Haberkorn, U. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.171397 · Cited by 636
Positron Emission Tomography-Computed Tomography Standardized Uptake Values in Clinical Practice and Assessing Response to Therapy
Kinahan, P. E., & Fletcher, J. W. (2010) · Seminars in Ultrasound, CT and MRI · doi:10.1053/j.sult.2010.10.001 · Cited by 631
MIRD pamphlet no. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates.
Siegel, J. A., Thomas, S. R., Stubbs, J. B., Mg, S., Hays, M. T., Koral, K. F., Robertson, J. S., Howell, R. W., Wessels, B. W., Fisher, D. R., et al. (1999) · PubMed · Cited by 572
177 Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy
Baum, R. P., Kulkarni, H., Schuchardt, C., Singh, A., Wirtz, M., Wiessalla, S., Schottelius, M., Müeller, D., Klette, I., & Wester, H. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.168443 · Cited by 532
Self-citation
Prostate-specific membrane antigen expression as a predictor of prostate cancer progression
Perner, S., Hofer, M. D., Kim, R., Shah, R. B., Li, H., Mӧller, P., Hautmann, R. E., Gschwend, J. E., Kuefer, R., & Rubin, M. A. (2007) · Human Pathology · doi:10.1016/j.humpath.2006.11.012 · Cited by 455

Show all 33 references

Sorted by citations

Dosimetry of 177 Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes
Violet, J., Jackson, P., Ferdinandus, J., Sandhu, S., Akhurst, T., Iravani, A., Kong, G., Kumar, A. R., Thang, S. P., Eu, P., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.219352 · Cited by 504
EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT)
Kratochwil, C., Fendler, W. P., Eiber, M., Baum, R. P., Bozkurt, M. F., Czernin, J. G., Bolton, R. C. D., Ezziddin, S., Forrer, F., Hicks, R. J., et al. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04485-3 · Cited by 387
Self-citation
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)
Kratochwil, C., Fendler, W. P., Eiber, M., Hofman, M. S., Emmett, L., Calais, J., Osborne, J. R., Iravani, A., Koo, P. J., Lindenberg, L., et al. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-023-06255-8 · Cited by 339
Self-citation
Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of 177 Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer
Violet, J., Sandhu, S., Iravani, A., Ferdinandus, J., Thang, S.-P., Kong, G., Kumar, A. R., Akhurst, T., Pattison, D., Beaulieu, A., et al. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.236414 · Cited by 292
EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands
Gleisner, K. S., Chouin, N., Gabiña, P. M., Cicone, F., Gnesin, S., Stokke, C., Konijnenberg, M., Cremonesi, M., Verburg, F. A., Bernhardt, P., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05727-7 · Cited by 284
Theranostics in nuclear medicine practice
Yordanova, A., Eppard, E., Kürpig, S., Bundschuh, R. A., Schönberger, S., Gonzalez-Carmona, M. A., Feldmann, G., Ahmadzadehfar, H., & Essler, M. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s140671 · Cited by 249
Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy
Eiber, M. J., Fendler, W. P., Rowe, S. P., Calais, J., Hofman, M. S., Maurer, T., Schwarzenboeck, S. M., Kratowchil, C., Herrmann, K., & Giesel, F. L. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.186767 · Cited by 243
Self-citation
Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade
Patel, R. B., Hernandez, R. T., Carlson, P. M., Grudzinski, J. J., Bates, A. M., Jagodinsky, J. C., Erbe, A. K., Marsh, I. R., Arthur, I. S., Aluicio‐Sarduy, E., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abb3631 · Cited by 230
Prostate-Specific Membrane Antigen Radioligand Therapy Using 177 Lu-PSMA I&T and 177 Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: Comparison of Safety, Biodistribution, and Dosimetry
Schuchardt, C., Zhang, J., Kulkarni, H., Chen, X. S., Müller, D., & Baum, R. P. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262713 · Cited by 187
TheraP: a randomized phase 2 trial of 177 Lu‐ PSMA ‐617 theranostic treatment vs cabazitaxel in progressive metastatic castration‐resistant prostate cancer (Clinical Trial Protocol ANZUP 1603)
Hofman, M. S., Emmett, L., Violet, J. A., Zhang, A. Y., Lawrence, N. J., Stockler, M. R., Francis, R. J., Iravani, A., Williams, S., Azad, A., et al. (2019) · British Journal of Urology · doi:10.1111/bju.14876 · Cited by 166
Current status of theranostics in prostate cancer
Virgolini, I. J., Decristoforo, C., Haug, A. R., Fanti, S., & Uprimny, C. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3882-2 · Cited by 159
Radiation Dosimetry in 177Lu-PSMA-617 Therapy Using a Single Posttreatment SPECT/CT Scan: A Novel Methodology to Generate Time- and Tissue-Specific Dose Factors
Jackson, P. A., Hofman, M. S., Hicks, R. J., Scalzo, M., & Violet, J. A. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.233411 · Cited by 138
The 68Ga/177Lu theragnostic concept in PSMA targeting of castration-resistant prostate cancer: correlation of SUVmax values and absorbed dose estimates
Scarpa, L., Buxbaum, S., Kendler, D., Fink, K., Bektić, J., Gruber, L. N., Decristoforo, C., Uprimny, C., Lukas, P. H., Horninger, W., et al. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-016-3609-9 · Cited by 117
Targeted Radionuclide Therapy of Prostate Cancer—From Basic Research to Clinical Perspectives
Czerwińska, M., Bilewicz, A., Kruszewski, M. K., Węgierek-Ciuk, A., & Lankoff, A. (2020) · Molecules · doi:10.3390/molecules25071743 · Cited by 109
Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment
Jadvar, H. (2017) · American Journal of Roentgenology · doi:10.2214/ajr.17.18264 · Cited by 104
Uptake of PSMA-ligands in normal tissues is dependent on tumor load in patients with prostate cancer
Gaertner, F. C., Halabi, K., Ahmadzadehfar, H., Kürpig, S., Eppard, E., Kotsikopoulos, C., Liakos, N., Bundschuh, R. A., Strunk, H. M., & Essler, M. (2017) · Oncotarget · doi:10.18632/oncotarget.19049 · Cited by 100
Safety of Fibroblast Activation Protein–Targeted Radionuclide Therapy by a Low-Dose Dosimetric Approach Using 177Lu-FAPI04
Kuyumcu, S., Kovan, B., Şanlı, Y., Büyükkaya, F., Şimşek, D. H., Özkan, Z. G., Işık, E. G., Ekenel, M., & Türkmen, C. (2021) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000003667 · Cited by 99
First Clinicopathologic Evidence of a Non–PSMA-Related Uptake Mechanism for 68Ga-PSMA-11 in Salivary Glands
Rupp, N. J., Umbricht, C. A., Pizzuto, D. A., Lenggenhager, D. M., Töpfer, A., Müller, J., Muehlematter, U. J., Ferraro, D. A., Messerli, M., Morand, G. B., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.222307 · Cited by 97
Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns
Wahl, R. L., Sgouros, G., Iravani, A., Jacene, H., Pryma, D., Saboury, B., Capala, J., & Graves, S. A. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262751 · Cited by 95
Patients Resistant Against PSMA-Targeting α-Radiation Therapy Often Harbor Mutations in DNA Damage-Repair–Associated Genes
Kratochwil, C., Giesel, F. L., Heußel, C. P., Kazdal, D. N., Endris, V., Nientiedt, C., Bruchertseifer, F., Kippenberger, M., Rathke, H. G., Leichsenring, J., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.234559 · Cited by 92
Intra-therapeutic dosimetry of [177Lu]Lu-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer patients and correlation with treatment outcome
Peters, S. M. B., Privé, B. M., de Bakker, M., de Lange, F., Jentzen, W., Eek, A., Muselaers, C. H. J., Mehra, N., Witjes, J. A., Gotthardt, M., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05471-4 · Cited by 88
Quantitative SPECT: the time is now
Dickson, J. C., Ross, J. C., & Vöö, S. A. (2019) · EJNMMI Physics · doi:10.1186/s40658-019-0241-3 · Cited by 87
Tumor Sink Effect in 68Ga-PSMA-11 PET: Myth or Reality?
Gafita, A., Wang, H., Robertson, A., Armstrong, W. R., Zaum, R., Weber, M., Yagubbayli, F., Kratochwil, C., Grogan, T., Nguyen, K., et al. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.261906 · Cited by 85
Self-citation
Repeated 177Lu-Labeled PSMA-617 Radioligand Therapy Using Treatment Activities of Up to 9.3 GBq
Rathke, H. G., Giesel, F. L., Flechsig, P., Kopka, K., Mier, W., Hohenfellner, M., Haberkorn, U., & Kratochwil, C. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.194209 · Cited by 81
Recent advances in theranostics and challenges for the future
Turner, J. H. (2018) · British Journal of Radiology · doi:10.1259/bjr.20170893 · Cited by 79
The Effect of Total Tumor Volume on the Biologically Effective Dose to Tumor and Kidneys for 177Lu-Labeled PSMA Peptides
Begum, N. J., Thieme, A., Eberhardt, N., Tauber, R., D’Alessandria, C., Beer, A. J., Glatting, G., Eiber, M. J., & Kletting, P. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.203505 · Cited by 78
Self-citation
Renal and Multiorgan Safety of 177 Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer in the VISION Dosimetry Substudy
Herrmann, K., Rahbar, K., Eiber, M., Sparks, R. B., Baca, N., Krause, B. J., Laßmann, M., Jentzen, W., Tang, J., Chicco, D., et al. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.123.265448 · Cited by 81
Self-citation
[68Ga]Ga-PSMA-11 PET imaging as a predictor for absorbed doses in organs at risk and small lesions in [177Lu]Lu-PSMA-617 treatment
Peters, S. M. B., Hofferber, R., Privé, B. M., de Bakker, M., Gotthardt, M., Janssen, M. J. R., de Lange, F., Muselaers, S., Mehra, N., Witjes, J. A., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05538-2 · Cited by 78
Dosimetry in radionuclide therapy: the clinical role of measuring radiation dose
Lawhn-Heath, C., Hope, T. A., Martinez, J., Fung, E. K., Shin, J., Seo, Y., & Flavell, R. R. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00657-4 · Cited by 77
Radionuclide Therapy of Metastatic Prostate Cancer
Kratochwil, C., Haberkorn, U., & Giesel, F. L. (2019) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2019.02.003 · Cited by 76
Biodistribution and dosimetry of a single dose of albumin-binding ligand [177Lu]Lu-PSMA-ALB-56 in patients with mCRPC
Kramer, V., Fernández, R., Lehnert, W., Jiménez‐Franco, L. D., Soza‐Ried, C., Eppard, E., Ceballos, M., Meckel, M., Benešová, M., Umbricht, C. A., et al. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-05022-3 · Cited by 73
Dosimetry of [177Lu]Lu-PSMA–Targeted Radiopharmaceutical Therapies in Patients with Prostate Cancer: A Comparative Systematic Review and Metaanalysis
Ells, Z., Grogan, T., Czernin, J. G., Dahlbom, M., & Calais, J. (2024) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.267452 · Cited by 73
Modeling and Predicting Tumor Response in Radioligand Therapy
Kletting, P., Thieme, A., Eberhardt, N., Rinscheid, A., D’Alessandria, C., Allmann, J., Wester, H., Tauber, R., Beer, A. J., Glatting, G., et al. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.210377 · Cited by 67
Self-citation
Theranostics of prostate cancer: from molecular imaging to precision molecular radiotherapy targeting the prostate specific membrane antigen
Kulkarni, H., Singh, A., Langbein, T., Schuchardt, C., Müeller, D., Zhang, J., Lehmann, C., & Baum, R. P. (2018) · British Journal of Radiology · doi:10.1259/bjr.20180308 · Cited by 61
Advances in PSMA theranostics
Jeitner, T. M., Babich, J. W., & Kelly, J. M. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101450 · Cited by 62
The 68Ga/177Lu-theragnostic concept in PSMA-targeting of metastatic castration–resistant prostate cancer: impact of post-therapeutic whole-body scintigraphy in the follow-up
Maffey-Steffan, J., Scarpa, L., Svirydenka, A., Nilica, B., Mair, C., Buxbaum, S., Bektić, J., von Guggenberg, E., Uprimny, C., Horninger, W., et al. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04583-2 · Cited by 60
Development of [225Ac]Ac-PSMA-I&T for Targeted Alpha Therapy According to GMP Guidelines for Treatment of mCRPC
Hooijman, E. L., Chalashkan, Y., Ling, S. W., Kahyargil, F. F., Segbers, M., Bruchertseifer, F., Morgenstern, A., Seimbille, Y., Koolen, S. L. W., Brabander, T., et al. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13050715 · Cited by 59
Renal Safety of [177Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Compromised Baseline Kidney Function
Rosar, F., Kochems, N., Bartholomä, M. D., Maus, S., Stemler, T., Linxweiler, J., Khreish, F., & Ezziddin, S. (2021) · Cancers · doi:10.3390/cancers13123095 · Cited by 59
[161Tb]Tb-PSMA-617 radioligand therapy in patients with mCRPC: preliminary dosimetry results and intra-individual head-to-head comparison to [177Lu]Lu-PSMA-617
Schaefer-Schuler, A., Burgard, C., Blickle, A., Maus, S., Petrescu, C., Petto, S., Bartholomä, M. D., Stemler, T., Ezziddin, S., & Rosar, F. (2024) · Theranostics · doi:10.7150/thno.92273 · Cited by 60
Imaging-guided targeted radionuclide tumor therapy: From concept to clinical translation
Sun, J., Huangfu, Z., Yang, J., Wang, G., Hu, K., Gao, M., & Zhong, Z. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114538 · Cited by 57
Influence of sampling schedules on [177Lu]Lu-PSMA dosimetry
Rinscheid, A., Kletting, P., Eiber, M., Beer, A. J., & Glatting, G. (2020) · EJNMMI Physics · doi:10.1186/s40658-020-00311-0 · Cited by 56
Self-citation
Dosimetric Analysis of the Short-Ranged Particle Emitter 161Tb for Radionuclide Therapy of Metastatic Prostate Cancer
Bernhardt, P., Svensson, J. B., Hemmingsson, J., van der Meulen, N. P., Zeevaart, J. R., Konijnenberg, M., Müller, C., & Kindblom, J. (2021) · Cancers · doi:10.3390/cancers13092011 · Cited by 55
Comparison of different methods for post-therapeutic dosimetry in [177Lu]Lu-PSMA-617 radioligand therapy
Rosar, F., Schön, N., Bohnenberger, H., Bartholomä, M. D., Stemler, T., Maus, S., Khreish, F., Ezziddin, S., & Schaefer-Schuler, A. (2021) · EJNMMI Physics · doi:10.1186/s40658-021-00385-4 · Cited by 56
Radiation Dosimetry in 177Lu-PSMA-617 Therapy
Jackson, P. A., Hofman, M. S., McIntosh, L., Buteau, J. P., & Kumar, A. S. R. (2021) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2021.11.003 · Cited by 58
Biodistribution and radiation dosimetry of [64Cu]copper dichloride: first-in-human study in healthy volunteers
Ávila‐Rodríguez, M. A., Ríos, C., Carrasco-Hernández, J., Manrique-Arias, J. C., Martinez‐Hernandez, R., García-Pérez, F. O., Jalilian, A. R., Martinez-Rodriguez, E., Romero-Piña, M., & Dı́az-Ruiz, A. (2017) · EJNMMI Research · doi:10.1186/s13550-017-0346-4 · Cited by 54
Dosimetry in Clinical Radiopharmaceutical Therapy of Cancer: Practicality Versus Perfection in Current Practice
Pandit-Taskar, N. D., Iravani, A., Lee, D., Jacene, H. A., Pryma, D. A., Hope, T. A., Saboury, B., Capala, J., & Wahl, R. L. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262977 · Cited by 55
Salivary Gland Toxicity of PSMA-Targeted Radioligand Therapy with 177Lu-PSMA and Combined 225Ac- and 177Lu-Labeled PSMA Ligands (TANDEM-PRLT) in Advanced Prostate Cancer: A Single-Center Systematic Investigation
Langbein, T., Kulkarni, H., Schuchardt, C., Müeller, D., Volk, G. F., & Baum, R. P. (2022) · Diagnostics · doi:10.3390/diagnostics12081926 · Cited by 53
Application of machine learning to pretherapeutically estimate dosimetry in men with advanced prostate cancer treated with 177Lu-PSMA I&T therapy
Xue, S., Gafita, A., Dong, C., Zhao, Y. S., Tetteh, G., Menze, B. H., Ziegler, S. I., Weber, W., Afshar‐Oromieh, A., Rominger, A., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05883-w · Cited by 52
Self-citation
Extensive 177Lu-PSMA Radioligand Therapy Can Lead to Radiation Nephropathy with a Renal Thrombotic Microangiopathy–like Picture
Schäfer, H., Mayr, S., Büttner-Herold, M. J., Knorr, K., Steinhelfer, L., Böger, C. A., Gschwend, J. E., Heemann, U. W., Eiber, M. J., Schmaderer, C., et al. (2022) · European Urology · doi:10.1016/j.eururo.2022.05.025 · Cited by 51
Self-citation
Optimization of the radiation dosimetry protocol in Lutetium-177-PSMA therapy: toward clinical implementation
Peters, S. M. B., Mink, M. C. T., Privé, B. M., de Bakker, M., de Lange, F., Muselaers, S., Mehra, N., Witjes, J. A., Gotthardt, M., Nagarajah, J., et al. (2023) · EJNMMI Research · doi:10.1186/s13550-023-00952-z · Cited by 51
Relevant tumor sink effect in prostate cancer patients receiving 177Lu-PSMA-617 radioligand therapy
Filß, C., Heinzel, A., Miiller, B., Vogg, A. T. J., Langen, K., & Mottaghy, F. M. (2018) · Nuklearmedizin - NuclearMedicine · doi:10.3413/nukmed-0937-17-10 · Cited by 49
Early Experience of Rechallenge 177Lu-PSMA Radioligand Therapy After an Initial Good Response in Patients with Advanced Prostate Cancer
Gafita, A., Rauscher, I., Retz, M. M., Knorr, K., Heck, M. M., Wester, H., D’Alessandria, C., Weber, W., Eiber, M., & Tauber, R. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.215715 · Cited by 48
Self-citation
Synthesis and Preclinical Evaluation of 177 Lu-Labeled Radiohybrid PSMA Ligands for Endoradiotherapy of Prostate Cancer
Wurzer, A. J., Kunert, J.-P., Fischer, S., Felber, V. B., Beck, R., Rose, F. D., D’Alessandria, C., Weber, W., & Wester, H. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.263371 · Cited by 47
Self-citation
Targeted nuclear medicine. Seek and destroy
Максимилианович, Т. В., Чернов, В. И., & Deyev, S. M. (2021) · Russian Chemical Reviews · doi:10.1070/rcr5034 · Cited by 47
Current research topics in FAPI theranostics: a bibliometric analysis
van den Hoven, A. F., Keijsers, R. G. M., Lam, M. G. E. H., Glaudemans, A. W. J. M., Verburg, F. A., Vogel, W. V., & Lavalaye, J. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-06052-9 · Cited by 47
Safety and Therapeutic Optimization of Lutetium-177 Based Radiopharmaceuticals
Ladrière, T., Faudemer, J., Levigoureux, E., Peyronnet, D., Desmonts, C., & Vigne, J. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041240 · Cited by 51
Albumin-Binding and Conventional PSMA Ligands in Combination with 161 Tb: Biodistribution, Dosimetry, and Preclinical Therapy
Tschan, V. J., Busslinger, S. D., Bernhardt, P., Grundler, P. V., Zeevaart, J. R., Köster, U., van der Meulen, N. P., Schibli, R., & Müller, C. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.123.265524 · Cited by 49
Clinical Perspectives of Theranostics
Okamoto, S., Shiga, T., & Tamaki, N. (2021) · Molecules · doi:10.3390/molecules26082232 · Cited by 46
Self-citation
89Zr-labeled PSMA ligands for pharmacokinetic PET imaging and dosimetry of PSMA-617 and PSMA-I&T: a preclinical evaluation and first in man
Privé, B. M., Derks, Y. H. W., Rosar, F., Franssen, G. M., Peters, S. M. B., Khreish, F., Bartholomä, M. D., Maus, S., Gotthardt, M., Laverman, P., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05661-0 · Cited by 46
Pretherapeutic 68Ga-PSMA-617 PET May Indicate the Dosimetry of 177Lu-PSMA-617 and 177Lu-EB-PSMA-617 in Main Organs and Tumor Lesions
Wang, J., Zang, J., Wang, H., Liu, Q., Li, F., Lin, Y., Huo, L., Jacobson, O., Niu, G., Fan, X., et al. (2019) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000002575 · Cited by 43
Current use and future potential of (physiologically based) pharmacokinetic modelling of radiopharmaceuticals: a review
Siebinga, H., der Veen, B. J. D. W., Stokkel, M. P. M., Huitema, A. D. R., & Hendrikx, J. J. M. A. (2022) · Theranostics · doi:10.7150/thno.77279 · Cited by 39
Prostate-Specific Membrane Antigen (PSMA) Theranostics for Treatment of Oligometastatic Prostate Cancer
Plichta, K. A., Graves, S. A., & Buatti, J. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212095 · Cited by 40
Radiation dosimetry of [68Ga]PSMA-11 in low-risk prostate cancer patients
Sandgren, K., Johansson, L. F., Axelsson, J., Jonsson, J. H., Ögren, M., Ögren, M., Andersson, M., Strandberg, S., Nyholm, T., Riklund, K., et al. (2019) · EJNMMI Physics · doi:10.1186/s40658-018-0239-2 · Cited by 38
Preclinical investigations using [177Lu]Lu-Ibu-DAB-PSMA toward its clinical translation for radioligand therapy of prostate cancer
Tschan, V. J., Borgna, F., Busslinger, S. D., Stirn, M., Rodríguez, J. M. M., Bernhardt, P., Schibli, R., & Müller, C. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05837-2 · Cited by 38
How Can Radiopharmaceutical Therapies Reach Their Full Potential? Improving Dose Reporting and Phase I Clinical Trial Design
Kiess, A. P., O’Donoghue, J. A., Uribe, C., Bodei, L., Hobbs, R. F., Hesterman, J. Y., Kesner, A., Sgouros, G., Bäck, T. A., Bardiès, M., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.01241 · Cited by 39
Pharmacological Optimization of PSMA-Based Radioligand Therapy
van der Gaag, S., Bartelink, I. H., Vis, A. N., Burchell, G. L., Oprea‐Lager, D. E., & Hendrikse, H. (2022) · Biomedicines · doi:10.3390/biomedicines10123020 · Cited by 37
[44Sc]Sc-PSMA-617 Biodistribution and Dosimetry in Patients With Metastatic Castration-Resistant Prostate Carcinoma
Khawar, A., Eppard, E., Sinnes, J., Roesch, F., Ahmadzadehfar, H., Kürpig, S., Meisenheimer, M., Gaertner, F. C., Essler, M., & Bundschuh, R. A. (2018) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000002003 · Cited by 37
Pretherapeutic Comparative Dosimetry of177Lu-rhPSMA-7.3 and177Lu-PSMA I&T in Patients with Metastatic Castration-Resistant Prostate Cancer
Feuerecker, B., Chantadisai, M., Allmann, A., Tauber, R., Allmann, J., Steinhelfer, L., Rauscher, I., Wurzer, A. J., Wester, H., Weber, W., et al. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262671 · Cited by 34
Self-citation
Prediction of Response to 177 Lu-PSMA Therapy Based on Tumor-to-Kidney Ratio on Pretherapeutic PSMA PET/CT and Posttherapeutic Tumor-Dose Evaluation in mCRPC
Hohberg, M., Reifegerst, M., Drzezga, A. E., Wild, M., & Schmidt, M. C. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.122.264953 · Cited by 34
Reduction of 68Ga-PSMA renal uptake with mannitol infusion: preliminary results
Matteucci, F., Mezzenga, E., Caroli, P., Iorio, V. D., Sarnelli, A., Celli, M., Fantini, L., Moretti, A., Galassi, R., Giorgi, U. D., et al. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3791-4 · Cited by 34
A review of 177Lu dosimetry workflows: how to reduce the imaging workloads?
Vergnaud, L., Dewaraja, Y. K., Giraudet, A., Badel, J., & Sarrut, D. (2024) · EJNMMI Physics · doi:10.1186/s40658-024-00658-8 · Cited by 34
Kidney absorbed radiation doses for [177Lu]Lu-PSMA-617 and [177Lu]Lu-PSMA-I&T determined by 3D clinical dosimetry
Uijen, M. J. M., Privé, B. M., van Herpen, C. M. L., Westdorp, H., van Gemert, W. A., de Bakker, M., Gotthardt, M., Konijnenberg, M., Peters, S. M. B., & Nagarajah, J. (2023) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000001658 · Cited by 33
Correction to: The 68Ga/177Lu-theragnostic concept in PSMA-targeting of metastatic castration–resistant prostate cancer: impact of post-therapeutic whole-body scintigraphy in the follow-up
Maffey-Steffan, J., Scarpa, L., Svirydenka, A., Nilica, B., Mair, C., Buxbaum, S., Bektić, J., von Guggenberg, E., Uprimny, C., Horninger, W., et al. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04660-6 · Cited by 32
Dual‐time‐point 64 Cu‐PSMA ‐617‐ PET/CT in patients suffering from prostate cancer
Hoberück, S., Wunderlich, G., Michler, E., Hölscher, T., Walther, M., Seppelt, D., Platzek, I., Zöphel, K., & Kotzerke, J. (2019) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.3745 · Cited by 32
Pre-therapy PET-based voxel-wise dosimetry prediction by characterizing intra-organ heterogeneity in PSMA-directed radiopharmaceutical theranostics
Xue, S., Gafita, A., Zhao, Y. S., Mercolli, L., Cheng, F., Rauscher, I., D’Alessandria, C., Seifert, R., Afshar‐Oromieh, A., Rominger, A., et al. (2024) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-024-06737-3 · Cited by 31
Self-citation
177Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer
Şanlı, Y., Şimşek, D. H., Şanlı, Ö., Subramaniam, R. M., & Kendi, A. T. (2021) · Biomedicines · doi:10.3390/biomedicines9040430 · Cited by 30
Individual radiosensitivity reflected by γ-H2AX and 53BP1 foci predicts outcome in PSMA-targeted radioligand therapy
Widjaja, L., Werner, R. A., Krischke, E., Christiansen, H., Bengel, F. M., Bogdanova, N. V., & Derlin, T. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05974-8 · Cited by 30
A phase 1 trial to determine the maximum tolerated dose and patient-specific dosimetry of [177Lu]Lu-LNC1003 in patients with metastatic castration-resistant prostate cancer
Zang, J., Wang, G., Zhao, T., Liu, H., Lin, X., Yang, Y., Shao, Z., Wang, C., Chen, H., Chen, Y., et al. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-023-06470-3 · Cited by 30
[68Ga]PSMA-HBED-CC Uptake in Osteolytic, Osteoblastic, and Bone Marrow Metastases of Prostate Cancer Patients
Janssen, J.-C., Woythal, N., Meißner, S., Prasad, V., Brenner, W., Diederichs, G., Hamm, B., & Makowski, M. R. (2017) · Molecular Imaging and Biology · doi:10.1007/s11307-017-1101-y · Cited by 30
Lesion Dosimetry for [ 177 Lu]Lu-PSMA-617 Radiopharmaceutical Therapy Combined with Stereotactic Body Radiotherapy in Patients with Oligometastatic Castration-Sensitive Prostate Cancer
Grkovski, M., O’Donoghue, J. A., Imber, B. S., Andl, G., Tu, C., Lafontaine, D., Schwartz, J., Thor, M., Zeléfsky, M. J., Humm, J. L., et al. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.123.265763 · Cited by 29
Labelling of 90 Y- and 177 Lu-DOTA-Bioconjugates for Targeted Radionuclide Therapy: A Comparison among Manual, Semiautomated, and Fully Automated Synthesis
Iori, M., Capponi, P. C., Rubagotti, S., Esposizione, L. R., Seemann, J., Pitzschler, R., Dreger, T., Formisano, D., Grassi, E., Fioroni, F., et al. (2017) · Contrast Media & Molecular Imaging · doi:10.1155/2017/8160134 · Cited by 29
Comparative Preclinical Biodistribution, Dosimetry, and Endoradiotherapy in Metastatic Castration-Resistant Prostate Cancer Using 19 F/ 177 Lu-rhPSMA-7.3 and 177 Lu-PSMA I&T
Yusufi, N., Wurzer, A. J., Herz, M., D’Alessandria, C., Feuerecker, B., Weber, W., Wester, H., Nekolla, S. G., & Eiber, M. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.254516 · Cited by 29
Self-citation
Prediction of Normal Organ Absorbed Doses for [177Lu]Lu-PSMA-617 Using [44Sc]Sc-PSMA-617 Pharmacokinetics in Patients With Metastatic Castration Resistant Prostate Carcinoma
Khawar, A., Eppard, E., Sinnes, J., Roesch, F., Ahmadzadehfar, H., Kürpig, S., Meisenheimer, M., Gaertner, F. C., Essler, M., & Bundschuh, R. A. (2018) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000002102 · Cited by 28
Evolving Role of PET in Detecting and Characterizing Atherosclerosis
Høilund‐Carlsen, P. F., Moghbel, M. C., Gerke, O., & Alavi, A. A. (2019) · PET Clinics · doi:10.1016/j.cpet.2018.12.001 · Cited by 28
Investigation of image-based lesion and kidney dosimetry protocols for 177Lu-PSMA-I&T therapy with and without a late SPECT/CT acquisition
Resch, S., Fouladgar, S. T., Zacherl, M. J., Sheikh, G. T., Liubchenko, G., Rumiantcev, M., Unterrainer, L. M., Wenter, V., Bartenstein, P., Ziegler, S. I., et al. (2023) · EJNMMI Physics · doi:10.1186/s40658-023-00529-8 · Cited by 28
Self-citation
Prostate-specific Membrane Antigen–based Imaging of Castration-resistant Prostate Cancer
Weber, M., Hadaschik, B. A., Ferdinandus, J., Rahbar, K., Bögemann, M., Herrmann, K., Fendler, W. P., & Kesch, C. V. (2021) · European Urology Focus · doi:10.1016/j.euf.2021.01.002 · Cited by 28
Self-citation
Influence of dosimetry method on bone lesion absorbed dose estimates in PSMA therapy: application to mCRPC patients receiving Lu-177-PSMA-I&T
Brosch-Lenz, J., Uribe, C., Gosewisch, A., Kaiser, L., Todica, A. S., Ilhan, H., Gildehaus, F. J., Bartenstein, P., Rahmim, A., Celler, A. M., et al. (2021) · EJNMMI Physics · doi:10.1186/s40658-021-00369-4 · Cited by 27
Self-citation
Examining Absorbed Doses of Indigenously Developed 177 Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer Patients at Baseline and During Course of Peptide Receptor Radioligand Therapy
Kamaldeep, Wanage, G., Sahu, S., Maletha, P., Adnan, A., Suman, S., Basu, S. K., Das, T., & Banerjee, S. (2020) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2020.3640 · Cited by 26
Kidney Doses in 177Lu-Based Radioligand Therapy in Prostate Cancer: Is Dose Estimation Based on Reduced Dosimetry Measurements Feasible?
Mix, M. D., Renaud, T., Kind, F., Nemer, U., Yousefzadeh‐Nowshahr, E., Moalosi, T. C. G., Ormrane, A. M., Meyer, P. T., & Ruf, J. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262245 · Cited by 26
Initial clinical experience with [177Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer: dosimetry, safety, and efficacy from the lead-in cohort of the SPLASH trial
Hansen, A. R., Probst, S., Beauregard, J., Viglianti, B. L., Michalski, J. M., Tagawa, S. T., Sartor, O., Tutrone, R. F., Jr., Öz, O. K., Courtney, K. D., et al. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2024.1483953 · Cited by 25
Dose Calculations and Dose-Effect Relationships in 177Lu-PSMA I&T Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer
Barna, S., Haug, A. R., Hartenbach, M., Rasul, S., Grubmüller, B., Kramer, G., & Blaickner, M. (2020) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000003157 · Cited by 25
Individualization of Radionuclide Therapies: Challenges and Prospects
Piwowarska-Bilska, H., Kurkowska, S., & Birkenfeld, B. (2022) · Cancers · doi:10.3390/cancers14143418 · Cited by 26
177Lu-DOTA-HYNIC-Lys(Nal)-Urea-Glu: Biokinetics, Dosimetry, and Evaluation in Patients with Advanced Prostate Cancer
Santos‐Cuevas, C., Ferro‐Flores, G., García-Pérez, F. O., Jiménez‐Mancilla, N., Ramírez-Nava, G., Ocampo‐García, B., Luna‐Gutiérrez, M., Azorin‐Vega, E. P., Davanzo, J., & Soldevilla-Gallardo, I. (2018) · Contrast Media & Molecular Imaging · doi:10.1155/2018/5247153 · Cited by 24
Patient dosimetry of 177Lu-PSMA I&T in metastatic prostate cancer treatment: the experience in Thailand
Chatachot, K., Shiratori, S., Chaiwatanarat, T., & Khamwan, K. (2021) · Annals of Nuclear Medicine · doi:10.1007/s12149-021-01659-8 · Cited by 23
Kidney Protection with the Radical Scavenger α1-Microglobulin (A1M) during Peptide Receptor Radionuclide and Radioligand Therapy
Kristiansson, A., Örbom, A., Timmermand, O. V., Ahlstedt, J., Strand, S., & Åkerström, B. (2021) · Antioxidants · doi:10.3390/antiox10081271 · Cited by 23
Recent Advances in Prostate-Specific Membrane Antigen-Based Radiopharmaceuticals
Diao, W., Cai, H., Chen, L., Jin, X., Liao, X., & Jia, Z. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190201100739 · Cited by 22
(Radio)Theranostic Patient Management in Oncology Exemplified by Neuroendocrine Neoplasms, Prostate Cancer, and Breast Cancer
Velikyan, I. (2020) · Pharmaceuticals · doi:10.3390/ph13030039 · Cited by 22
Characterization of Effective Half-Life for Instant Single-Time-Point Dosimetry Using Machine Learning
Gomes, C. V., Chen, Y., Rauscher, I., Xue, S., Gafita, A., Hu, J., Seifert, R., Mercolli, L., Brosch-Lenz, J., Hong, J., et al. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.268175 · Cited by 21
Self-citation
Predictive factors of tumor sink effect: Insights from 177Lu-Prostate-specific membrane antigen therapy
Tuncel, M., Telli, T., Tuncalı, M. Ç., & Karabulut, E. (2021) · Annals of Nuclear Medicine · doi:10.1007/s12149-021-01593-9 · Cited by 22
Bone marrow dosimetry in low volume mHSPC patients receiving Lu-177-PSMA therapy using SPECT/CT
Grob, D., Privé, B. M., Muselaers, S., Mehra, N., Nagarajah, J., Konijnenberg, M., & Peters, S. M. B. (2024) · EJNMMI Physics · doi:10.1186/s40658-024-00636-0 · Cited by 21

Authors: Okamoto, S., Thieme, A., Allmann, J., D’Alessandria, C., Maurer, T., Retz, M., Tauber, R., Heck, M. M., Wester, H.-J., Tamaki, N., Fendler, W. P., Herrmann, K., Pfob, C. H., Scheidhauer, K., Schwaiger, M., Ziegler, S., & Eiber, M.
Affiliations: Hokkaido University (JP)
TUM Klinikum (DE)
Technical University of Munich (DE)
University of California, Los Angeles (US)
ORCID: Okamoto, Shozo
D’Alessandria, Calogero
Maurer, Tobias
Tauber, Robert
Heck, Matthias M.
Tamaki, Nagara
Fendler, Wolfgang P.
Herrmann, Ken
Pfob, Christian H.
Schwaiger, Markus
Ziegler, Sibylle
Eiber, Matthias
Venue: Journal of Nuclear Medicine
Publisher: Society of Nuclear Medicine
Published: 2016-09-22
Volume: 58
Issue: 3
Pages: 445-450
ISSN: 0161-5505 (ISSN-L)
2159-662X
DOI: 10.2967/jnumed.116.178483
OpenAlex: W2523192478
Cited by: 213
References: 33
Citations by year: 2026: 10 · 2025: 26 · 2024: 31 · 2023: 21 · 2022: 27 · 2021: 36 · 2020: 13 · 2019: 22 · 2018: 15 · 2017: 12
FWCI: 14.18
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Journal of Nuclear Medicine (publishedVersion)
PubMed (publishedVersion)
Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
Topics: Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
Keywords: 177Lu-PSMA-I&T, radioligand therapy, metastatic castration-resistant prostate cancer, absorbed dose, tumor dose, OLINDA/EXM, dosimetry, parotid gland, lacrimal gland, kidney dose, liver dose
MeSH terms: Aged, Dipeptides, Heterocyclic Compounds, 1-Ring, Humans, Lutetium, Male, Metabolic Clearance Rate, Neoplasm Metastasis, Organ Specificity, Radiotherapy Dosage, Retrospective Studies, Tissue Distribution, Whole-Body Counting, Treatment Outcome, Prostate-Specific Antigen, Radiopharmaceuticals, Positron-Emission Tomography, Organ Sparing Treatments, Prostatic Neoplasms, Castration-Resistant, Absorption, Radiation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Radiation Dosimetry for 177 Lu-PSMA I&T in Metastatic Castration-Resistant Prostate Cancer: Absorbed Dose in Normal Organs and Tumor Lesions

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks